A New Staging System for Hereditary Transthyretin Amyloidosis in the Era of Specific Amyloidosis Therapies
We propose a novel staging system for ATTRv patients on specific treatment, based on two biological markers and one echocardiographic parameter, common in clinical practice.
Authors
- Gabriela Neculae (ORCID: https://orcid.org/0000-0003-1764-3291)
- Benoît Funalot (ORCID: https://orcid.org/0000-0001-6352-6518)
- Robert Adam (ORCID: https://orcid.org/0000-0002-5018-1482)
- Ruxandra Jurcuţ (ORCID: https://orcid.org/0000-0002-3438-2612)
- Daniel Coriu (ORCID: https://orcid.org/0000-0002-7251-6079)
- Mounira Kharoubi (ORCID: https://orcid.org/0000-0001-8942-2506)
- Amira Zaroui (ORCID: https://orcid.org/0000-0002-4827-4057)
- Thibaud Damy
Institutions
- Inserm (FR)
- Carol Davila University of Medicine and Pharmacy (RO)
- Université Paris-Est Créteil (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Department of Health and Aged Care (AU)
- Institutul de Urgenţă pentru Boli Cardiovasculare "Prof.Dr. C.C. Iliescu" (RO)
- Amyloidosis Foundation (US)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Institut Mondor de Recherche Biomédicale (FR)
- Institutul Clinic Fundeni (RO)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1002/ehf2.15414
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer